8 results match your criteria: "Children's Hospital and University of Helsinki[Affiliation]"
Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
J Pediatr Gastroenterol Nutr
December 2022
From the Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Objectives: Escalation of the ustekinumab (UST) maintenance dosage was effective in adults with Crohn disease (CD), but no data are available for children. We evaluated the effectiveness and safety of dose escalation of UST in pediatric CD.
Methods: This was a retrospective multicenter study from 25 centers affiliated with the IBD Interest and Porto groups of ESPGHAN.
Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea.
J Crohns Colitis
October 2021
Assistance Publique - Hôpitaux de Paris, Hôpital Necker Enfants Malades, Pediatric Gastroenterology Hepatology and Nutrition, Paris, France.
Article Synopsis
- * An international study of 72 CLD patients found that 17% also had IBD, with a notably higher prevalence compared to general European rates, indicating a potential relationship between CLD and IBD.
- * Patients with both CLD and IBD often have growth issues and may require surgical interventions, highlighting the need for attentive management of these patients' health.
Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Leukemia
June 2020
Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
View Article and Find Full Text PDFMinimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Leukemia
June 2019
Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Minimal residual disease (MRD) measured by PCR of clonal IgH/TCR rearrangements predicts relapse in T-cell acute lymphoblastic leukemia (T-ALL) and serves as risk stratification tool. Since 10% of patients have no suitable PCR-marker, we evaluated flowcytometry (FCM)-based MRD for risk stratification. We included 274 T-ALL patients treated in the NOPHO-ALL2008 protocol.
View Article and Find Full Text PDFWho benefit from school doctors' health checks: a prospective study of a screening method.
BMC Health Serv Res
June 2018
Pikkujätti Medical Centre for Children and Youth, Helsinki, Finland.
Background: School health services provide an excellent opportunity for the detection and treatment of children at risk of later health problems. However, the optimal use of school doctors' skills and expertise remains unknown. Furthermore, no validated method for screening children for school doctors' assessments exists.
View Article and Find Full Text PDFObjectives: The aim of this study was to evaluate the current well-being and dietary restrictions in children 6 years after food challenge-confirmed diagnosis of non-IgE cow's milk protein allergy, compared to peers with gastrointestinal symptoms but negative food challenge. This study aimed to evaluate the diagnostic process retrospectively.
Methods: This is an Internet-based survey for mothers whose children underwent 6 years ago the double-blind, placebo-controlled food challenge for cow's milk (CM) because of gastrointestinal symptoms causing suspicion of non-IgE CM protein allergy.
Good responses but high TRM in adult patients after MSC therapy for GvHD.
Bone Marrow Transplant
April 2017
Advanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland.
Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
J Pediatr Gastroenterol Nutr
February 2017
Department of Pediatric Gastroenterology, Helsinki University Hospital, Children's Hospital and University of Helsinki, Helsinki, Finland.
Objectives: Optimizing infliximab (IFX) treatment in pediatric patients with inflammatory bowel disease (IBD) by using serum infliximab (S-IFX) trough levels and antibodies to IFX is recommended. There is need for studies assessing this strategy in clinical practice.
Methods: We retrospectively identified all pediatric patients with IBD (n = 146, median age 14.